Noah Degaetano in Sunnyvale, California

Home California Sunnyvale

Noah Degaetano has Psychiatry as his primary medical specialty. Their primary office is: 877 W Fremont Ave in Sunnyvale, California.

They're a part of the: David Carreon Md Inc medical group which has around 3 members. You can call their office at 650-993-9996 to schedule an appointment. They also accept the Medicare-approved amount as payment in full. They attended Icahn School Of Medicine At Mount Sinai and graduated in 2005 (around 19 years of experience). They are listed as doing telehealth appointments.

Noah Degaetano Office Phone and Directions

Noah Degaetano
David Carreon Md Inc
877 W Fremont Ave
Sunnyvale, California 94087
650-993-9996

Patient Ratings
Please rate your experience with Noah Degaetano below to help others make a more informed decision. Thanks!

Current Rating: Loading...

Phone: 650-993-9996

Enter a starting address:

Healthcare Info for Noah Degaetano

Medical School: Icahn School Of Medicine At Mount Sinai
Graduation Year: 2005
The Primary Medical Specialty for Noah Degaetano is listed as: Psychiatry
Approximate Years of Experience: 19
PAC (PECOS ID)#: 9830371228
NPI #: 1326247644
NPI Created On: 07/16/2007
NPI Last Updated Listed as: 06/03/2020
Primary Taxonomy Code: 2084P0800X
License Number:
244905
Listed Gender: Male

Procedures, Services, Charges

Services and Procedures include:

Psychiatric diagnostic evaluation with medical services
Psychotherapy, 30 minutes
Established patient office or other outpatient visit, typically 15 minutes
Established patient office or other outpatient, visit typically 25 minutes

Open Payments Data. This can include items to test (Durable Medical Equipment (DME)), Biological, Drug Samples, etc. This data must be reported to CMS.

Payments Total: $76

Number of Payments:: 1

Form of Payment: In-kind items and services

Record ID:: 837995771

Being Disputed:: No

Product Related: Yes

Drug or Biological: Drug

Product Category #1: PARKINSONS DISEASE PSYCHOSIS

Name of Drug #1: NUPLAZID

Open Associated Drug #1: 63090-170-60